Showing 4951-4960 of 7117 results for "".
- Chris Greta Appointed Chief Creative Officer at eRelevancehttps://practicaldermatology.com/news/chris-greta-appointed-chief-creative-officer-at-erelevance/2457996/Chris Greta has been appointed as the first chief creative officer for
- Menlo Therapeutics Expands Management Teamhttps://practicaldermatology.com/news/menlo-therapeutics-expands-management-team/2458006/Menlo Therapeutics Inc., a late stage biopharmaceutical company, is developing a neurokinin 1 (NK‐1) receptor antagonist (serlopitant) for the treatment of pruritus associated with various underlying conditions, and for the treatment of refractory chronic cough. The company, which continues to ad
- PruGen Pharmaceuticals Takes Action to Aid Hurricane Relief Effortshttps://practicaldermatology.com/news/prugen-pharmaceuticals-takes-action-to-aid-hurricane-relief-efforts/2458007/In the wake of several devastating and destructive hurricanes in the continental US and Puerto Rico, PruGen Pharmaceuticals is helping to those in need. The PruGen Foundation, a nonprofit organization founded by PruGen Pharmaceuticals and focused on philanthropic
- Ortho Dermatologics: Long-term Efficacy Data for Siliqhttps://practicaldermatology.com/news/ortho-dermatologics-long-term-efficacy-data-for-siliq/2458009/Siliq™ (brodalumab) injection provided sustained high levels of skin clearance (PASI 100) over more than two years in patients with moderate-to-severe psoriasis, according to data presented at the 2017 Fall Clinical Dermatology Conference in Las Vegas and reported by
- ASDS Elects New Officers, Board Membershttps://practicaldermatology.com/news/asds-elects-new-officers-board-members/2458016/The American Society for Dermatologic Surgery (ASDS) introduced their new Vice Presid
- EADV News: Positive Study Results for Dupixent® (dupilumab) in Patients With Moderate-to-Severe ADhttps://practicaldermatology.com/news/eadv-news-positive-study-results-for-dupixent-dupilumab-in-patients-with-moderate-to-severe-ad/2458050/Dupixent with topical corticosteroids (TCS) significantly improved measures of overall disease severity, skin clearing, itching, and patient reported quality of life measure in adults with moderate-to-severe atopic dermatitis (AD) who are inadequately controlled or intolerant to cyclosporine A (C
- Five-Year Data Show Sustained Efficacy, Safety for Cosentyxhttps://practicaldermatology.com/news/five-year-data-show-sustained-efficacy-safety-for-cosentyx/2458054/Novartis’ IL-17 blocker Cosentyx® (secukinumab) maintains PASI 90 and PASI 100 response rates at five years in patients with moderate to severe plaque psoriasis, according to new Phase III data. These data were presented for
- Women of Color May Be Disproportionately Exposed to Beauty Product Chemicalshttps://practicaldermatology.com/news/women-of-color-may-be-disproportionately-exposed-to-beauty-product-chemicals/2458087/Women with skin of color have higher levels of beauty-product related chemicals in their bodies compared to white women, according to a commentary published in the American Journal of Obstetrics and Gynecology.<
- New Criteria Aims to Help Doctors Spot Amelanotic Melanoma Earlierhttps://practicaldermatology.com/news/new-criteria-aims-to-help-doctors-spot-amelanotic-melanoma-earlier/2458092/New research outlines key features linked to amelanotic melanoma. The findings, which appear in JAMA Dermatology, may help improve detection of this type of melanoma, which is more likely to be diagnosed at advanced stages because it falls outside of the “ABCDE” guide
- Aclaris Submits Marketing Authorization Application in Europe for A-101 40% for Seborrheic Keratosishttps://practicaldermatology.com/news/aclaris-submits-marketing-authorization-application-in-europe-for-a-101-40-for-seborrheic-keratosis/2458100/Aclaris Therapeutics, Inc. has submitted a Marketing Authorization Application (MAA) with the Medicines Product Agency (MPA) in Sweden for its product candidate A-101 40% Topical Solution for the treatment of seborrheic keratosis. The MPA will act as the reference member state in this decentraliz